▲ +22.88% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $77.50, with a high forecast of $94.00 and a low forecast of $48.00. The average price target represents a 22.88% upside from the last price of $63.07.
The current consensus among 12 contributing investment analysts is to buy stock in Pacira BioSciences. This rating has held steady since November 2019, when it changed from a Hold consensus rating.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.